Skip to Content
Merck
CN
  • Targeting leukocidin-mediated immune evasion protects mice from Staphylococcus aureus bacteremia.

Targeting leukocidin-mediated immune evasion protects mice from Staphylococcus aureus bacteremia.

The Journal of experimental medicine (2020-07-01)
Kayan Tam, Keenan A Lacey, Joseph C Devlin, Maryaline Coffre, Alexis Sommerfield, Rita Chan, Aidan O'Malley, Sergei B Koralov, P'ng Loke, Victor J Torres
ABSTRACT

Staphylococcus aureus is responsible for various diseases in humans, and recurrent infections are commonly observed. S. aureus produces an array of bicomponent pore-forming toxins that target and kill leukocytes, known collectively as the leukocidins. The contribution of these leukocidins to impair the development of anti-S. aureus adaptive immunity and facilitate reinfection is unclear. Using a murine model of recurrent bacteremia, we demonstrate that infection with a leukocidin mutant results in increased levels of anti-S. aureus antibodies compared with mice infected with the WT parental strain, indicating that leukocidins negatively impact the generation of anti-S. aureus antibodies in vivo. We hypothesized that neutralizing leukocidin-mediated immune subversion by vaccination may shift this host-pathogen interaction in favor of the host. Leukocidin-immunized mice produce potent leukocidin-neutralizing antibodies and robust Th1 and Th17 responses, which collectively protect against bloodstream infections. Altogether, these results demonstrate that blocking leukocidin-mediated immune evasion can promote host protection against S. aureus bloodstream infection.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Human IgG ELISA Kit, for serum, plasma